Compare ARQT & ABG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | ABG |
|---|---|---|
| Founded | 2016 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail-Auto Dealers and Gas Stations |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2020 | 2001 |
| Metric | ARQT | ABG |
|---|---|---|
| Price | $28.84 | $170.30 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 11 |
| Target Price | $38.38 | ★ $237.64 |
| AVG Volume (30 Days) | ★ 2.9M | 257.0K |
| Earning Date | 10-27-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | 16.88 |
| EPS | 0.03 | ★ 16.20 |
| Revenue | $376,072,000.00 | ★ $17,999,000,000.00 |
| Revenue This Year | $43.01 | N/A |
| Revenue Next Year | $27.70 | $4.13 |
| P/E Ratio | $970.00 | ★ $10.49 |
| Revenue Growth | ★ 91.34 | 4.71 |
| 52 Week Low | $19.30 | $160.30 |
| 52 Week High | $31.77 | $258.75 |
| Indicator | ARQT | ABG |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 37.61 |
| Support Level | $24.91 | N/A |
| Resistance Level | $30.30 | $203.19 |
| Average True Range (ATR) | 1.20 | 6.02 |
| MACD | 0.32 | 0.70 |
| Stochastic Oscillator | 84.07 | 38.79 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Asbury Automotive Group is a regional collection of automobile dealerships that went public in March 2002. The company operates 158 new-vehicle stores and 37 collision centers. Over 70% of new-vehicle revenue is from luxury and import brands. Asbury also offers third-party financing and insurance products and its own F&I products via Total Care Auto. Asbury operates in 14 states (mostly in Rocky Mountain states, Texas, the Northeast, and Southeast). Asbury store brands include Herb Chambers in the Northeast, McDavid and Park Place in Texas, Koons in the Washington, D.C., area, and the Larry H. Miller brand in the Western US. Asbury generated about $18 billion of revenue in 2025 and is based in the Atlanta area. The firm targets at least $30 billion of revenue sometime around 2030.